Zynquista for Regulating Blood Sugar in Diabetes
Zynquista FAQ
Does Zynquista improve glycaemic control?
Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m 2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy. How useful was this page?
When is Zynquista used?
It is used in overweight patients (body mass index of at least 27 kg/m2) when insulin on blood sugar well enough. Zynquista contains the active substance sotagliflozin. How is Zynquista used? Zynquista is available as 200 mg tablets. The recommended meal of the day.
Does Zynquista work with insulin?
Zynquista, taken together with insulin, is effective in lowering blood glucose levels in patients with type 1 diabetes whose blood sugar is not controlled well enough with insulin alone. In addition, patients treated with the medicine have beneficial reductions in weight and blood pressure.
What is Sotagliflozin (Zynquista)?
Sotagliflozin (Zynquista™) is a dual inhibitor of sodium-glucose co-transporters (SGLT) 1 and 2 being developed by Lexicon Pharmaceuticals and Sanofi as a treatment for type 1 (T1DM) and type 2 diabetes mellitus (T2DM). The drug has a dual action, blunting and delaying absorption of glucose from the …
Does Zynquista control blood glucose levels?
Zynquista was found effective at controlling blood glucose levels in 3 main studies in patients with type 1 diabetes. In two of these studies, involving a total of 1,575 patients, two doses of Zynquista (200 and 400 mg) were compared with placebo when given in addition to insulin.
Zynquista References
If you want to know more about Zynquista, consider exploring links below:
What Is Zynquista
- https://www.ema.europa.eu/en/documents/overview/zynquista-epar-medicine-overview_en.pdf
- https://patient-info.co.uk/zynquista-70809/patient-leaflet
- https://en.wikipedia.org/wiki/Sotagliflozin
- https://pubmed.ncbi.nlm.nih.gov/31172412/
- https://www.diabetes.co.uk/news/2019/apr/european-commission-approves-zynquista-for-type-1-diabetes-92090696.html
- https://www.sanofi.com/en/media-room/press-releases/2019/2019-07-26-20-05-00-1892525
Zynquista Information
Explore Related Topics
The Role of SGLT-2 Inhibitors in Type 2 Diabetes Management
Delve into how SGLT-2 inhibitors work, their benefits, and considerations for use in treating type 2 diabetes